Mon Sep 09 15:40:12 UTC 2024: ## Virax Biolabs Presents at H.C. Wainwright’s 26th Annual Global Investment Conference

**NEW YORK, NY – September 9, 2024** – Virax Biolabs (VRAX), a biotechnology company specializing in immune response detection and viral disease diagnosis, announced that Chief Operating Officer Dr. Nigel McCracken presented at the H.C. Wainwright’s 26th Annual Global Investment Conference. The presentation, which is now available on-demand, highlighted Virax’s focus on developing T-Cell-based test technologies for immunology profiling.

Virax is actively researching and developing these technologies with the aim of providing a comprehensive platform for diagnosing and treating post-acute infection syndromes like Long COVID and other chronic conditions linked to immune dysregulation.

Dr. McCracken’s presentation covered Virax’s innovative approach and the potential of its technology in revolutionizing diagnostic and therapeutic methods. The presentation is available online at https://ir.viraxbiolabs.com.

Virax management is also available for one-on-one meetings during the conference. Interested parties can request a meeting through the company’s investor relations contact.

**About Virax Biolabs**
Virax Biolabs is an innovative biotechnology company dedicated to the detection of immune responses to and diagnosis of viral diseases. The company’s focus on developing T-Cell-based test technologies positions it as a leader in the field of immunology profiling.

**For more information, please visit http://www.viraxbiolabs.com.**

Read More